Treatment of Felty's syndrome with low-dose oral methotrexate

Authors

  • Lisa Sherbin Allen MD,

    1. Department of Medicine, Section of Rheumatology, Lehigh Valley Hospital Center, Allentown, Pennsylvania
    Search for more papers by this author
  • Dr. Gerald Groff MD

    Corresponding author
    1. Department of Medicine, Section of Rheumatology, Lehigh Valley Hospital Center, Allentown, Pennsylvania
    • Department of Medicine, Mary Imogene Bassett Hospital, Cooperstown, NY 13326
    Search for more papers by this author

Abstract

Recent studies of methotrexate in the treatment of patients with rheumatoid arthritis have precluded patients with neutropenia. We present a patient with rheumatoid arthritis complicated by severe neutropenia and recurrent infections, who was treated with low-dose methotrexate, orally, for 30 months. The patient experienced symptomatic improvement and a significant increase in granulocyte count, and the dosage of steroids was reduced. Low-dose oral methotrexate may be a therapeutic option in select patients with Felty's syndrome.

Ancillary